MA46988A1 - Formulation liquide d'anticorps anti-tnf alpha - Google Patents

Formulation liquide d'anticorps anti-tnf alpha

Info

Publication number
MA46988A1
MA46988A1 MA46988A MA46988A MA46988A1 MA 46988 A1 MA46988 A1 MA 46988A1 MA 46988 A MA46988 A MA 46988A MA 46988 A MA46988 A MA 46988A MA 46988 A1 MA46988 A1 MA 46988A1
Authority
MA
Morocco
Prior art keywords
liquid formulation
tnf alpha
alpha antibodies
antibodies
tnf
Prior art date
Application number
MA46988A
Other languages
English (en)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA46988A1 publication Critical patent/MA46988A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation liquide d'un anticorps anti-tnf alpha, en particulier l'adalimumab.
MA46988A 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha MA46988A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Publications (1)

Publication Number Publication Date
MA46988A1 true MA46988A1 (fr) 2020-06-30

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46988A MA46988A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Country Status (14)

Country Link
JP (2) JP7109849B2 (fr)
KR (2) KR20180106974A (fr)
CN (1) CN110621303A (fr)
AU (1) AU2018236651B2 (fr)
CO (1) CO2019010860A2 (fr)
MA (1) MA46988A1 (fr)
MX (1) MX2019010895A (fr)
MY (1) MY197202A (fr)
NZ (1) NZ757965A (fr)
PH (1) PH12019502075A1 (fr)
RU (1) RU2756619C2 (fr)
UA (1) UA123847C2 (fr)
WO (1) WO2018169348A1 (fr)
ZA (1) ZA201906696B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂
TWI861073B (zh) * 2019-03-21 2024-11-11 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF
CA3187322A1 (fr) * 2020-07-13 2022-01-20 Merck Patent Gmbh Excipients reducteurs de viscosite et leurs combinaisons pour formulations de proteines hautement concentrees
KR20230167025A (ko) * 2021-02-17 2023-12-07 압테보 리서치 앤드 디벨롭먼트 엘엘씨 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도
JPWO2025013783A1 (fr) 2023-07-07 2025-01-16

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR20160105535A (ko) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
WO2014114651A1 (fr) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison à l'antigène tnf-alpha
UY35460A (es) * 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
WO2015134406A1 (fr) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Préparations aqueuses stables de protéine recombinée
CA2944330A1 (fr) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Composition pharmaceutique liquide d'adalimumab
PL2946765T3 (pl) * 2014-05-23 2017-08-31 Ares Trading S.A. Ciekła kompozycja farmaceutyczna
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
EP3250598A1 (fr) * 2015-01-28 2017-12-06 Mabxience S.A. Formulations pharmaceutiques pour des anticorps anti-tnf-alpha
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Also Published As

Publication number Publication date
PH12019502075A1 (en) 2020-09-14
ZA201906696B (en) 2020-08-26
WO2018169348A1 (fr) 2018-09-20
CN110621303A (zh) 2019-12-27
AU2018236651B2 (en) 2020-12-10
BR112019019162A2 (pt) 2020-04-14
RU2019130728A3 (fr) 2021-04-16
KR102342292B1 (ko) 2021-12-24
RU2756619C2 (ru) 2021-10-04
CO2019010860A2 (es) 2020-01-17
NZ757965A (en) 2022-07-01
RU2019130728A (ru) 2021-04-16
MY197202A (en) 2023-05-31
KR20200096472A (ko) 2020-08-12
JP2022097600A (ja) 2022-06-30
KR20180106974A (ko) 2018-10-01
JP7109849B2 (ja) 2022-08-01
UA123847C2 (uk) 2021-06-09
AU2018236651A1 (en) 2019-10-31
MX2019010895A (es) 2019-11-05
JP2020510079A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA45450B1 (fr) Formulations d'anticorps anti-cd19
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MY197202A (en) A liquid formulation of anti-tnf alpha antibody
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
CO6270369A2 (es) Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
EA202192405A1 (ru) Составы антител против il-36r
MA38413A1 (fr) Anticorps pan-elr+ cxc chimiokine
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
EA201992027A1 (ru) Водный состав антитела против pd-l1
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EP3805390A4 (fr) Anticorps monoclonal nav1.7
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
MY199149A (en) Antibody that binds to vegf and il-1beta and methods of use
EP3947466A4 (fr) Anticorps anti-hla-dq2.5